 |
|
Parental Cardiovascular Disease as a Risk Factor for Cardiovascular Disease in Middle-aged Adults
A Prospective Study of Parents and Offspring
Donald M. Lloyd-Jones, MD, ScM;
Byung-Ho Nam, PhD;
Ralph B. D'Agostino Sr, PhD;
Daniel Levy, MD;
Joanne M. Murabito, MD, ScM;
Thomas J. Wang, MD;
Peter W. F. Wilson, MD;
Christopher J. O'Donnell, MD, MPH
JAMA. 2004;291:2204-2211.
ABSTRACT
| |
Context Whether parental cardiovascular disease confers increased risk independent of other risk factors remains controversial. Prior studies relied on offspring report, without complete validation of parental events.
Objective To determine whether parental cardiovascular disease predicts offspring events independent of traditional risk factors, using a prospective design for both parents and offspring, and uniform criteria to validate events.
Design Inception cohort study.
Setting Framingham Heart Study, a US population-based epidemiologic cohort begun in 1948 with the offspring cohort established in 1971.
Participants All Framingham Offspring Study participants (aged  30 years) who were free of cardiovascular disease and both parents in the original Framingham cohort.
Main Outcome Measures We examined the association of parental cardiovascular disease with 8-year risk of offspring cardiovascular disease, using pooled logistic regression.
Results Among 2302 men and women (mean age, 44 years), 164 men and 79 women had cardiovascular events during follow-up. Compared with participants with no parental cardiovascular disease, those with at least 1 parent with premature cardiovascular disease (onset age <55 years in father, <65 years in mother) had greater risk for events, with age-adjusted odds ratios of 2.6 (95% confidence interval [CI], 1.7-4.1) for men and 2.3 (95% CI, 1.3-4.3) for women. Multivariable adjustment resulted in odds ratios of 2.0 (95% CI, 1.2-3.1) for men and 1.7 (95% CI, 0.9-3.1) for women. Nonpremature parental cardiovascular disease and parental coronary disease were weaker predictors. Addition of parental information aided in discriminating event rates, notably among offspring with intermediate levels of cholesterol and blood pressure, as well as intermediate predicted multivariable risk.
Conclusions Using validated events, we found that parental cardiovascular disease independently predicted future offspring events in middle-aged adults. Addition of parental information may help clinicians and patients with primary prevention of cardiovascular disease, when treatment decisions may be difficult in patients at intermediate risk based on levels of single or multiple risk factors. These data also support further research into genetic determinants of cardiovascular risk.
INTRODUCTION
An offspring report of a positive parental history of cardiovascular disease (CVD), particularly if premature at onset, is a widely accepted risk factor for offspring cardiovascular events. Current guidelines1-2 recommend consideration of a positive parental history of premature coronary heart disease when deciding whether to initiate antihyperlipidemic or antihypertensive therapy for primary prevention. However, the true magnitude of independent risk that is conferred by the occurrence of parental CVD remains controversial. This uncertainty exists in large part because available data examining the association between parental and offspring CVD are derived from retrospective case-control studies3-7 or longitudinal studies8-20 relying on offspring self-report, with limited or absent validation of parental events. Offspring report of parental history may be highly unreliable,21-25 in part due to recall bias, and may lead to inflated estimates of risk associated with parental CVD. The effect of parental CVD on offspring risk across strata of individual risk factors is also not well understood.
We sought to determine whether validated parental occurrence of CVD is an independent, prospective predictor of offspring cardiovascular events. Accurate estimates of the relationship between parental and offspring cardiovascular events could provide stronger evidence for the clinical emphasis on prevention in patients with a positive parental history. The Framingham Heart Study is uniquely suited to perform such an analysis given its longitudinal follow-up and exhaustive documentation of events in both parents and offspring.
METHODS
Study Sample and Definitions
The Framingham Heart Study was established in 1948, when 5209 residents of Framingham, Mass, aged 28 to 62 years, were enrolled in a prospective epidemiologic cohort study. Members of this original cohort have undergone follow-up evaluations every 2 years. In 1971, an additional 5124 participants (offspring of original cohort subjects and their spouses) were enrolled in the Framingham Offspring Study (offspring cohort). These participants have undergone follow-up evaluations every 4 years. Study design and entry criteria for both cohorts have been detailed elsewhere.26-27All participants have provided written informed consent at each examination, and all study protocols have been approved by the Institutional Review Board of Boston University School of Medicine.
We included all Framingham Offspring Study participants who were aged 30 years or older and free of prevalent CVD and for whom both parents were followed up in the original cohort. Parental subjects were followed up from 1948 to 2001, and offspring participants were followed up from 1971 to 2001. Given the structure of follow-up examinations, we elected to study the 8-year incidence of cardiovascular events in the offspring cohort. We focused on atherosclerotic cardiovascular events since atherosclerosis is believed to be the mechanism underlying familial aggregation. Using previously published Framingham Heart Study criteria28 to validate parental and offspring events, we defined a cardiovascular event as the occurrence of coronary death, myocardial infarction, coronary insufficiency, angina pectoris, atherothrombotic stroke, intermittent claudication, or cardiovascular death. Hard coronary heart disease events were defined as coronary death, myocardial infarction, or hospitalized coronary insufficiency only. Premature parental CVD was defined as the occurrence of a validated parental event prior to an offspring baseline examination and before age 55 years in a father or age 65 years in a mother. These age cut points were drawn from the recommendations of the National Cholesterol Education Program Third Adult Treatment Panel (ATP-III)1 and Seventh Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7).2
Statistical Analysis
We used pooled logistic regression analyses to examine the risks of incident offspring cardiovascular events associated with positive parental CVD over 8 years after an examination. This person-time method of pooling person-examinations accounts for time-dependent covariance of risk factors and parental cardiovascular events and has been shown to provide valid estimates of effect similar to using time-dependent Cox analyses. This is a robust assumption, as demonstrated by D'Agostino et al.29 Participants contributed a mean of 2.2 person-examination cycles. For all logistic regression analyses, the reference group consisted of offspring participants with no parental CVD prior to the time of the offspring examination. Odds ratios (ORs) and 95% confidence intervals (CIs) were calculated in unadjusted analyses, as well as after adjustment for offspring age, age with other individual categories of cardiovascular risk factors, and all other risk factors in the model. These analyses were repeated examining parental nonpremature CVD and parental hard coronary heart disease as risk factors for offspring CVD. Risk factor covariates, chosen a priori for inclusion in the models and updated using pooled logistic analyses, were: offspring age, systolic blood pressure, total cholesterol/high-density lipoprotein cholesterol (HDL-C) ratio, body mass index, presence of diabetes, current smoking, and use of antihypertensive drug therapy. In the multivariable models, there was only 1 significant first-order interaction (between maternal CVD and antihypertensive therapy in men). Inclusion of the interaction term did not alter the substance of our findings, so it was excluded from the models.
A multivariable risk score was calculated using weighted coefficients for each covariate, with the exception of parental CVD information. Offspring participants were stratified into quintiles of predicted multivariable risk for CVD. Eight-year event rates were then compared for participants in each quintile, as well as across clinical strata of individual risk factors, according to presence or absence of parental CVD, using  2 tests. C statistics were calculated for the model before and after inclusion of parental CVD information. All statistical analyses were performed using SAS statistical software version 8 (SAS Institute, Cary, NC). A 2-tailed P value less than .05 was defined as statistically significant.
RESULTS
Baseline Characteristics
The study sample included 1128 men and 1174 women offspring participants who were free of CVD at a mean age of 44 years. Characteristics of these individuals are shown in Table 1. During follow-up, 164 men and 79 women had incident cardiovascular events, of which 14 (5.7%) were coronary deaths (11 [4.5%], sudden; 3 [1.2%], nonsudden), 5 (2.1%) were other cardiovascular deaths, 76 (31.3%) were nonfatal myocardial infarction or coronary insufficiency, 71 (29.2%) were angina pectoris, 39 (16.0%) were stroke, and 38 (15.6%) were intermittent claudication. There was a similar distribution of event types among parents.
|
|
|
|
Table 1. Characteristics of Offspring Subjects at Baseline Examinations*
|
|
|
Parental CVD and Offspring Risk
The ORs for offspring cardiovascular events associated with premature parental CVD are shown in Table 2. After adjustment for offspring age, the ORs associated with parental CVD were 2.6 (95% CI, 1.7-4.1) for men and 2.3 (95% CI, 1.3-4.3) for women. Additional adjustment for individual risk factors did not substantially attenuate the risk associated with parental CVD further (Table 2). After multivariable adjustment for offspring age and all other risk factors, parental occurrence of CVD remained a significant predictor of offspring events in men. In women, the multivariable association was of borderline statistical significance. In age-adjusted and multivariable-adjusted analyses, the ORs for offspring CVD were higher for premature (Table 2) than for nonpremature parental CVD (Table 3).
|
|
|
|
Table 2. Risk for Offspring Cardiovascular Disease Over 8 Years, by Presence of Premature Parental Cardiovascular Disease
|
|
|
|
|
|
|
Table 3. Risk for Offspring Cardiovascular Disease Over 8 Years, by Presence of Nonpremature Parental Cardiovascular Disease
|
|
|
The occurrence in 1 or more parent of premature hard coronary disease only was less strongly associated with risk for CVD, with multivariable ORs of 1.7 (95% CI, 1.0-2.8) for men and 1.2 (95% CI, 0.5-2.5) for women offspring. Because 1737 of the 2302 offspring were part of a sibship, a given parent's event may have been counted more than once in these analyses. When we restricted the analysis to 1 sibling per family (the oldest), the results were not changed substantially.
Offspring Event Rates by Parental CVD and Risk Factors
When we stratified participants by levels of individual risk factors, parental information added substantially to discrimination of observed 8-year event rates. Table 4 shows the 8-year cardiovascular event rates for offspring men and women, separately and combined, without and with premature parental CVD. The overall event rate was 44/1000 (4.4%) over 8 years. Although absolute event rates were lower for women than they were for men, the overall pattern of effect was similar. When we stratified by offspring age, parental CVD was associated with significantly higher offspring event rates with a 3-fold difference for offspring aged 30 to 59 years, and a 2-fold difference for older offspring.
|
|
|
|
Table 4. Eight-Year Cardiovascular Disease Event Rates per 1000 for Men and Women Separately and Combined, According to Presence or Absence of Parental Premature Cardiovascular Disease, Stratified by Individual Risk Factor Levels
|
|
|
Parental CVD increased offspring risk across all strata of total cholesterol levels and blood pressure measurements. The greatest relative differences in event rates were observed among participants with borderline levels of cholesterol and high-normal blood pressure. Premature parental CVD increased risk in these intermediate subsets to the point that the 10-year risks of CVD would exceed 10%, a threshold for treatment used in some clinical guidelines. Premature parental CVD was also associated with increased risk among both smokers and nonsmokers, as well as among those who did not have diabetes. However, parental CVD did not significantly increase risk among diabetic participants, who already had substantially higher event rates.
Eight-year cardiovascular event rates are displayed in Figure 1 for offspring according to quintile of predicted multivariable risk. Observed 8-year event rates increased markedly and in a stepwise fashion from lowest to highest quintile. At very low and very high predicted risk, the increase in event rates associated with the presence of premature parental CVD was modest: offspring with favorable risk factor profiles were not at substantially increased risk despite parental CVD, and offspring with very unfavorable risk factor profiles remained at high risk even in the absence of parental CVD. In the intermediate quintiles, premature parental CVD was associated with significantly higher cardiovascular event rates (Figure 1).
|
|
|
|
Figure. Offspring Cardiovascular Disease Event Rates by Predicted Risk and Presence of Premature Parental CVD
Offspring participants were stratified into quintiles of predicted risk of cardiovascular disease based on factors listed in the "Methods" section.
|
|
|
In a separate analysis, we stratified offspring according to their predicted absolute 10-year risk for hard coronary events, as estimated by the ATP-III risk equations.1 Premature parental CVD presence vs absence was associated with increased events among offspring predicted to be at low risk by ATP-III (n = 3093; 54/1000 vs 18/1000 events over 8 years, respectively; P<.001). There was a nonsignificant difference in the ATP-III intermediate-risk group (n = 153; 200/1000 vs 138/1000, respectively; P = .33), but there were few participants, particularly women, in the ATP-III intermediate-risk (n = 9 women) and high-risk (n = 29 women) groups due to the young age of the offspring sample.
Receiver Operating Characteristic Analyses and Attributable Risk
Inclusion of premature parental CVD as a covariate altered the c statistic (area under the receiver operating characteristic curve) for our multivariable model predicting offspring CVD from 0.80 to 0.81 for men and from 0.81 to 0.82 for women. When men and women were combined, inclusion of premature parental CVD in the multivariable model altered the c statistic from 0.82 to 0.83. The attributable risk percentages for premature parental CVD were 29.0% in men and 20.6% in women offspring; for nonpremature parental CVD, they were 20.5% and 5.8%, respectively.
COMMENT
Principal Findings
Using a prospective design to ascertain both parental and offspring events, we found that the occurrence of parental CVD is an independent predictor of offspring cardiovascular events in middle-aged men and women. After adjustment for other risk factors, premature CVD in at least 1 parent was associated with a significant doubling in cardiovascular risk for men and a 70% increase (nonsignificant) in risk for women over 8 years. Premature parental CVD was found to discriminate risk best among offspring with intermediate levels of cardiovascular risk as predicted by individual traditional risk factors or multivariable risk equations.
We focused on a cohort of middle-aged offspring because parental CVD is likely to be a greater factor in determining relative CVD risk in younger than older individuals, as our findings confirm (Table 4). Adjustment for offspring age markedly attenuated the association of parental and offspring CVD. This may reflect the fact that older subjects also have older parents, who have had a longer lifespan in which to experience a cardiovascular event unrelated to familial aggregation. Multivariable adjustment for age and other traditional risk factors further attenuated the risk associated with parental CVD, and these covariates accounted for the majority of the crude risk associated with parental CVD. A significant, but modest, residual risk remained associated with parental occurrence of CVD, suggesting that parental CVD is a clinically important aggregate marker of both heritable risk factors and as yet unmeasured genetic risk factors.
Clinical Implications
These results should help to inform clinicians and patients about use of parental history in risk stratification and treatment decisions. It should be noted that the validation of parental events available for this study is not available in most clinical settings. Nevertheless, our results shed important light on the true magnitude of the association between offspring and parental CVD. It is likely that clinicians place greater importance on positive parental CVD in younger compared with older patients, which appears appropriate in terms of relative risk. However, at present it is difficult for clinicians and patients to know how to assess and incorporate into clinical practice the risk associated with parental CVD, independent of shared risk factors. As expected, we observed a substantial, stepwise increase in the incidence of CVD across quintiles of multivariable risk as estimated by multivariable equations using a combination of traditional, modifiable risk factors (Figure 1). Recent studies confirm that these traditional risk factors are present in almost all patients who develop CVD,30-31 and that they account for the majority of risk.32-33 Thus, clinicians and patients must continue to focus on proven lifestyle and drug therapies to modify traditional risk factors and reduce risk.
The addition of parental data may aid in discriminating risk most among men and women at intermediate levels of predicted risk. Knowledge of parental CVD status may not change the magnitude of risk substantially for those at very high or very low predicted risk. For patients with intermediate predicted risk, however, the additional information provided by positive parental CVD may change the posttest probability enough to consider altering the treatment of the patient. Treatment decisions in current guidelines are based on absolute risk levels. We demonstrate significantly higher 8-year absolute rates of CVD among participants with borderline cholesterol or blood pressure levels and premature compared with no parental CVD (Table 4). It is precisely these patients in whom decisions about lifestyle modification or drug treatment may be the most difficult. Thus, our data support the emphasis placed by the ATP-III1 and JNC 7 guidelines on ascertainment of parental history2 to help guide treatment decisions for primary prevention. Furthermore, our findings support consideration of clinical trials to assess the benefits of aggressive risk-factor modification in intermediate risk patients with parental CVD.
Our data also suggest that incorporation of validated parental data into multivariable functions predicting 10-year absolute risks for cardiovascular or coronary disease1, 34-35 may increase the predictive accuracy of such functions,36 although perhaps only to a small extent. The overall c statistic for our multivariable model increased from 0.82 to 0.83 by adding parental CVD information. It has proved difficult to make marked improvements in risk stratification over and above incorporation of traditional risk factors, even with novel markers such as C-reactive protein.37-39
Ongoing work is examining the utility of including parental occurrence of CVD or other novel risk markers in updated Framingham coronary risk functions. The addition of parental information to traditional risk factors must certainly be considered in the development of these risk functions. However, in the formulation of updated risk functions, a number of novel risk markers should also be considered. It may well be that inclusion of such markers will improve risk prediction better than incorporation of family history.
Research Implications
There is ample evidence for familial aggregation of traditional risk factors, as well as associations of parental and sibling CVD with adverse lipids and other risk factors in offspring.40-42 Parental history has also been associated with novel markers of inflammation,43 lipoprotein(a) and fibrinogen,43-45 and measures of subclinical atherosclerosis.46-50 Familial aggregation of these risk factors suggests genetic influence on the causal pathways of familial cardiovascular risk and explains the attenuation in ORs that we observed after multivariable adjustment. The significant residual risk associated with parental history after multivariable adjustment suggests that additional pathways for familial clustering merit further investigation.
Current Study in Perspective
Numerous case-control studies3-7 have reported approximately 2- to 5-fold higher prevalence of a positive familial history among subjects with manifest CVD than among control subjects. Large, prospective cohort studies8-20 also have generally found a positive association between self-reported parental or familial history and multivariable-adjusted relative risks for offspring CVD, with estimates ranging from 0.8 to 2.2. Our results shed further light on the true magnitude of this association.
Our study benefited from several unique methodologic strengths. First, as this was a prospective study, parental events were ascertained and validated independently and prior to the occurrence of offspring events, avoiding recall bias and inaccuracy inherent in offspring self-report.21-25 Both parental and offspring events were validated using consistent, standardized definitions after review of all medical records by a panel of 3 physicians.28 Many studies have relied on death certificate data to identify or confirm parental events, which may lead to substantial overdiagnosis of coronary disease, especially in older decedents.51
Our study also benefited from the long duration of follow-up of both the parental and offspring family members. Shorter studies would miss parental events that have not yet occurred. At this point, ascertainment of premature events in parents is complete, and ascertainment of later parental events, near-complete. Our study design allowed for updating of parental history information and repeated measurements of offspring risk factors independent of parental history. Given these strengths, our estimates of the magnitude of the association between parental and offspring CVD may represent the most accurate published to date.
Limitations
The Framingham cohorts are almost exclusively white, which may limit the generalizability of our findings to other ethnic groups. Rates of use of preventive medications were fairly low, but could have contributed to reduction in risk associated with parental CVD if subjects with parental CVD were more likely to receive them. If anything, this would bias our results toward the null. We had relatively little power to find an independent relationship in women and to comment on any potential differences between paternal and maternal CVD as risk factors. Apparent differences in the magnitude of effect between offspring men and women may reflect the low number of cases and lower prevalence of risk factors in women. Finally, an unvalidated offspring report of parental history may not have the same clinical utility as the validated parental events used in the current study. However, risk estimates from studies using offspring self-report fall within the bounds of our study. With the current study design, we attempted to determine the most accurate possible representation of the association between parental and offspring CVD.
AUTHOR INFORMATION
| |
Corresponding Author: Christopher J. O'Donnell, MD, MPH, Framingham Heart Study, 73 Mt Wayte Ave, Suite No. 2, Framingham, MA 01702 (codonnell{at}nih.gov).
Author Contributions: Drs Lloyd-Jones and O'Donnell had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.
Study concept and design: Lloyd-Jones, Nam, D'Agostino, Levy, Murabito, Wang, Wilson, O'Donnell.
Acquisition of data: D'Agostino, Levy, Murabito, Wilson.
Analysis and interpretation of data: Lloyd-Jones, Nam, D'Agostino, Levy, Murabito.
Drafting of the manuscript: Lloyd-Jones.
Critical revision of the manuscript for important intellectual content: Lloyd-Jones, Nam, D'Agostino, Levy, Murabito, Wang, Wilson, O'Donnell.
Statistical expertise: Lloyd-Jones, Nam, D'Agostino, O'Donnell.
Obtained funding: D'Agostino.
Administrative, technical, or material support: Levy, O'Donnell.
Study supervision: Levy, O'Donnell.
Funding/Support: Dr Lloyd-Jones is supported by grant K23 HL04253 from the National Heart, Lung, and Blood Institute, National Institutes of Health. The Framingham Heart Study is supported by NIH/NHLBI contract N01-HC-25195.
Role of the Sponsor: The National Heart, Lung, and Blood Institute sponsors the Framingham Heart Study through a contract, but had no direct involvement in this analysis or any decision to publish.
Acknowledgment: We thank Leslie King, BA, for her assistance in researching prior studies of parental history and cardiovascular disease.
Author Affiliations: Department of Preventive Medicine and Division of Cardiology, Feinberg School of Medicine, Northwestern University, Chicago, Ill (Dr Lloyd-Jones); National Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, Mass (Drs Lloyd-Jones, Nam, D'Agostino, Levy, Murabito, Wang, Wilson, and O'Donnell); Statistics and Consulting Unit (Drs Nam and D'Agostino), Department of Epidemiology and Preventive Medicine, Boston University (Drs D'Agostino, Levy, Murabito, Wilson, and O'Donnell), and Section of General Internal Medicine, Boston University School of Medicine (Dr Murabito); Cardiology Division (Drs Wang and O'Donnell), Massachusetts General Hospital, Harvard Medical School, Boston; and National Heart, Lung, and Blood Institute, Bethesda, Md (Drs Levy and O'Donnell).
REFERENCES
1. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106:3143-3421.
FREE FULL TEXT
2. Chobanian AV, Bakris GL, Black HR, et al. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003;42:1206-1252.
FREE FULL TEXT
3. Friedlander Y, Siscovick DS, Weinmann S, et al. Family history as a risk factor for primary cardiac arrest. Circulation. 1998;97:155-160.
FREE FULL TEXT
4. Leander K, Hallqvist J, Reuterwall C, Ahlbom A, de Faire U. Family history of coronary heart disease, a strong risk factor for myocardial infarction interacting with other cardiovascular risk factors: results from the Stockholm Heart Epidemiology Program (SHEP). Epidemiology. 2001;12:215-221.
FULL TEXT
|
ISI
| PUBMED
5. Pohjola-Sintonen S, Rissanen A, Liskola P, Luomanmaki K. Family history as a risk factor of coronary heart disease in patients under 60 years of age. Eur Heart J. 1998;19:235-239.
FREE FULL TEXT
6. Roncaglioni MC, Santoro L, D'Avanzo B, et al, for the GISSI-EFRIM Investigators. Role of family history in patients with myocardial infarction: an Italian case-control study. Circulation. 1992;85:2065-2072.
FREE FULL TEXT
7. Shea S, Ottman R, Gabrieli C, Stein Z, Nichols A. Family history as an independent risk factor for coronary artery disease. J Am Coll Cardiol. 1984;4:793-801.
ABSTRACT
8. Barrett-Connor E, Khaw K. Family history of heart attack as an independent predictor of death due to cardiovascular disease. Circulation. 1984;69:1065-1069.
FREE FULL TEXT
9. Colditz GA, Stampfer MJ, Willett WC, Rosner B, Speizer FE, Hennekens CH. A prospective study of parental history of myocardial infarction and coronary heart disease in women. Am J Epidemiol. 1986;123:48-58.
FREE FULL TEXT
10. Colditz GA, Rimm EB, Giovannucci E, Stampfer MJ, Rosner B, Willett WC. A prospective study of parental history of myocardial infarction and coronary artery disease in men. Am J Cardiol. 1991;67:933-938.
FULL TEXT
|
ISI
| PUBMED
11. Friedlander Y, Kark JD, Stein Y. Family history of myocardial infarction as an independent risk factor for coronary heart disease. Br Heart J. 1985;53:382-387.
FREE FULL TEXT
12. Jousilahti P, Puska P, Vartiainen E, Pekkanen J, Tuomilehto J. Parental history of premature coronary heart disease: an independent risk factor of myocardial infarction. J Clin Epidemiol. 1996;49:497-503.
FULL TEXT
|
ISI
| PUBMED
13. Khaw KT, Barrett-Connor E. Family history of stroke as an independent predictor of ischemic heart disease in men and stroke in women. Am J Epidemiol. 1986;123:59-66.
FREE FULL TEXT
14. Myers RH, Kiely D, Cupples LA, Kannel WB. Parental history is an independent risk factor for coronary artery disease: the Framingham Study. Am Heart J. 1990;120:963-969.
FULL TEXT
|
ISI
| PUBMED
15. Phillips AN, Shaper AG, Pocock SJ, Walker M. Parental death from heart disease and the risk of heart attack. Eur Heart J. 1988;9:243-251.
FREE FULL TEXT
16. Sesso HD, Lee IM, Gaziano JM, Rexrode KM, Glynn RJ, Buring JE. Maternal and paternal history of myocardial infarction and risk of cardiovascular disease in men and women. Circulation. 2001;104:393-398.
FREE FULL TEXT
17. Sholtz RI, Rosenman RH, Brand RJ. The relationship of reported parental history to the incidence of coronary heart disease in the Western Collaborative Group Study. Am J Epidemiol. 1975;102:350-356.
FREE FULL TEXT
18. Silberberg JS, Wlodarczyk J, Fryer J, Robertson R, Hensley MJ. Risk associated with various definitions of family history of coronary heart disease: the Newcastle Family History Study II. Am J Epidemiol. 1998;147:1133-1139.
FREE FULL TEXT
19. Thelle DS, Forde OH. The cardiovascular study in Finnmark county: coronary risk factors and the occurrence of myocardial infarction in first degree relatives and in subjects of different ethnic origin. Am J Epidemiol. 1979;110:708-715.
FREE FULL TEXT
20. Williams RR, Hunt SC, Heiss G, et al. Usefulness of cardiovascular family history data for population-based preventive medicine and medical research (the Health Family Tree Study and the NHLBI Family Heart Study). Am J Cardiol. 2001;87:129-135.
FULL TEXT
|
ISI
| PUBMED
21. Bensen JT, Liese AD, Rushing JT, et al. Accuracy of proband reported family history: the NHLBI Family Heart Study. Genet Epidemiol. 1999;17:141-150.
FULL TEXT
|
ISI
| PUBMED
22. Kee F, Tiret L, Robo JY, et al. Reliability of reported family history of myocardial infarction. BMJ. 1993;307:1528-1530.
ISI
| PUBMED
23. Murabito JM, Nam BH, D'Agostino RB Sr, Lloyd-Jones DM, O'Donnell CJ, Wilson PW. Accuracy of reported parental history of cardiovascular risk factors and disease: the Framingham Offspring Study. Ann Intern Med. 2004;140:434-440.
FREE FULL TEXT
24. Silberberg JS, Wlodarczyk J, Fryer J, Ray CD, Hensley MJ. Correction for biases in a population-based study of family history and coronary heart disease: the Newcastle Family History Study I. Am J Epidemiol. 1998;147:1123-1132.
FREE FULL TEXT
25. Watt G, McConnachie A, Upton M, Emslie C, Hunt K. How accurately do adult sons and daughters report and perceive parental deaths from coronary disease? J Epidemiol Community Health. 2000;54:859-863.
FREE FULL TEXT
26. Dawber TR, Kannel WB, Lyell LP. An approach to longitudinal studies in a community: the Framingham Study. Ann N Y Acad Sci. 1963;107:539-556.
ISI
| PUBMED
27. Kannel WB, Feinleib M, McNamara PM, Garrison RJ, Castelli WP. An investigation of coronary heart disease in families: the Framingham Offspring Study. Am J Epidemiol. 1979;110:281-290.
FREE FULL TEXT
28. Abbott RD, McGee DL. The Framingham Study: An Epidemiological Investigation of Cardiovascular Disease, Section 37: The Probability of Developing Certain Cardiovascular Diseases in Eight Years at Specified Values of Some Characteristics. Bethesda, Md: National Heart, Lung, and Blood Institute; 1987.
29. D'Agostino RB, Lee ML, Belanger AJ, Cupples LA, Anderson KM, Kannel WB. Relation of pooled logistic regression to time dependent Cox regression analysis: the Framingham Heart Study. Stat Med. 1990;9:1501-1515.
ISI
| PUBMED
30. Greenland P, Knoll MD, Stamler J, et al. Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA. 2003;290:891-897.
FREE FULL TEXT
31. Khot UN, Khot MB, Bajzer CT, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA. 2003;290:898-904.
FREE FULL TEXT
32. Magnus P, Beaglehjole R. The real contribution of the major risk factors to the coronary epidemics. Arch Intern Med. 2001;161:2657-2660.
FREE FULL TEXT
33. Stamler J, Stamler R, Neaton JD, et al. Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy: findings for 5 large cohorts of young adult and middle-aged men and women. JAMA. 1999;282:2012-2018.
FREE FULL TEXT
34. Califf RM, Armstrong PW, Carver JR, D'Agostino RB, Strauss WE. Task Force 5: stratification of patients into high, medium and low risk subgroups for purposes of risk factor management. J Am Coll Cardiol. 1996;27:1007-1019.
FULL TEXT
|
ISI
| PUBMED
35. Wilson PW, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB. Prediction of coronary heart disease using risk factor categories. Circulation. 1998;97:1837-1847.
FREE FULL TEXT
36. Assmann G, Cullen P, Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the prospective cardiovascular Munster (PROCAM) study. Circulation. 2002;105:310-315.
FREE FULL TEXT
37. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557-1565.
FREE FULL TEXT
38. Koenig W, Lowel H, Baumert J, Meisinger C. C-reactive protein modulates risk prediction based on the Framingham score. Circulation. 2004;109:1349-1353.
FREE FULL TEXT
39. van der Meer IM, de Maat MP, Kiliaan AJ, van der Kuip DA, Hofman A, Witteman JC. The value of C-reactive protein in cardiovasculaqr risk prediction: the Rotterdam study. Arch Intern Med. 2003;163:1323-1328.
FREE FULL TEXT
40. Allen JK, Blumenthal RS. Risk factors in the offspring of women with premature coronary heart disease. Am Heart J. 1998;135:428-434.
FULL TEXT
|
ISI
| PUBMED
41. Becker DM, Yook RM, Moy TF, Blumenthal RS, Becker LC. Markedly high prevalence of coronary risk factors in apparently healthy African-American and white siblings of persons with premature coronary heart disease. Am J Cardiol. 1998;82:1046-1051.
FULL TEXT
|
ISI
| PUBMED
|
